Information about Actos and bladder cancer.
Welcome

Actos generated more than $16B in revenue

November 21st, 2014

Type 2 diabetes drug Actos has generated more than $16 billion since its release in 1999, according to court filings in lawsuits against the drug’s manufacturer, Takeda Pharmaceuticals. Lawyers have accused Takeda of putting profits before patients’ health by waiting nearly 7 years to issue a warning about the increased risks of cancer associated with Actos.   Actos sales peaked… read more »

Lawyer blames Takeda for putting Actos profits ahead of patient safety

November 21st, 2014

Attorneys in an Actos bladder cancer lawsuit have blamed manufacturer Takeda Pharmaceuticals for putting Actos profits ahead of patient safety. Lawyers alleged that Takeda executives knew as early as 2004 that their type 2 diabetes medicine Actos could greatly increase the risks of patients developing bladder cancer, but did not issue a warning until 7 years later in order to… read more »

Expert witness claims manufacturer hid Actos bladder cancer risks

October 3rd, 2014

An expert witness testifying on behalf of a plaintiff in an Actos bladder cancer lawsuit has alleged that manufacturer Takeda Pharmaceuticals intentionally hid bladder cancer risks. University of Georgia toxicologist Randall Tackett made the testimony on behalf of Frances Wisniewski, who says she developed bladder cancer after taking Actos to treat her type 2 diabetes. Tackett pointed to a correspondence… read more »

Actos manufacturers lose bid to overturn $9B punitive damages award

September 19th, 2014

Actos manufacturer Takeda Pharmaceuticals and its U.S. partner Eli Lilly & Co. lost a bid to have a judge overturn a $9 billion punitive damages award given in a recent Actos lawsuit. The judge ruled that the jury properly considered evidence showing that Takeda and Eli Lilly knew Actos caused bladder cancer but failed to warn patients and doctors. The… read more »

Jury awards $9 B in punitive damages for Actos bladder cancer lawsuit

September 5th, 2014

A jury awarded a couple $9 billion in punitive damages from drug manufacturer Takeda Pharmaceuticals and its U.S. distribution partner Eli Lilly. The jury also awarded $1.5 million in compensatory damages to the patient, Terrance Allen, who successfully argued Actos caused him to develop bladder cancer. read more »

Drop In Actos Usage Due to Bladder Cancer Risk

January 8th, 2014

According to Diabeteshealth.com, Glitazones, such as Actos, have seen a dramatic drop in usage over the past few years. Actos use among diabetes patients dropped from 41 percent in 2005 to 16 percent in 2012 due to drug’s link to cardiovascular issues and bladder cancer.… read more »

AARP questions safety of Actos

October 1st, 2012

The American Association of Retired Persons has released a newsletter in which a segment called “Ask the Pharmacist” questions the safety of diabetes drug Actos. Dr. Armon B. Neel Jr. highlighted the risks of taking the drug, which have recently been at the center of Actos lawsuits.… read more »

Consumer Reports warns against generic version of Actos

September 7th, 2012

Consumer Reports has warned readers against using a generic version of Actos recently approved by the Food and Drug Administration. The consumer awareness organization recommends that patients ask their doctors if using the brand-name diabetes drug Actos or its new generic equivalent is necessary, and recommends it only for patients who have no other options.… read more »

Actos may increase risk of macular edema

August 13th, 2012

Type II diabetes drug Actos may substantially increase the risk of macular edema, according to new research published in the Archives of Internal Medicine. The risk of developing the eye condition was 230% greater up to 10 years after use among patients taking the diabetes medication.… read more »

Doctor warns of pharmaceutical company influence on data in new book

July 16th, 2012

A prominent doctor and former Secretary of the British Association for Psychopharmacology warns of pharmaceutical companies manipulating data in a new book called “Pharmageddon.” Dr. David Healy argues in the book that companies like GlaxoSmithKline and Takeda Pharmaceuticals outsource clinical trials and hide data from health agencies.… read more »

Page 1 of 41234

Contact Us Today for a Free Consultation.

YesNo
I am currently represented by an attorney.
captcha
*Required fields